HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
Previously, we have reported a correlation between the expression of HER2/neu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2/neu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infiltrating lymphocytes of HLA-A2+ HER2/neu+ NSCLC patients. These CTL lines specifically recognized HLA-A2+ HER2/neu+ autologous and allogeneic NSCLC cell lines as well as HLA-A2+ HER2/neu+ heterologous ovarian cancer cell lines. Furthermore, these CTL recognized an overexpressed, HER2/neu-derived peptide. From these results, we conclude that HLA-A2 serves as a restriction element in NSCLC. More importantly, at least one HER2/neu-derived peptide is a tumor-associated antigen in NSCLC and ovarian cancer.
Duke Scholars
Published In
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tumor Cells, Cultured
- T-Lymphocytes, Cytotoxic
- Receptor, erbB-2
- Receptor, ErbB-2
- Proto-Oncogene Proteins
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Lung Neoplasms
- Humans
- HLA-A2 Antigen
Citation
Published In
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tumor Cells, Cultured
- T-Lymphocytes, Cytotoxic
- Receptor, erbB-2
- Receptor, ErbB-2
- Proto-Oncogene Proteins
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Lung Neoplasms
- Humans
- HLA-A2 Antigen